Læknablaðið : fylgirit - 01.05.1978, Síða 77

preparation. It disappeared completely after
about one month.
One patient had a slight pain at the injeetion
site, disappearing after a short time, about one
week. One patient (No. 8) complained over fever
reaction, 39°, of short duration (some hours)
beginning immediately after the injections, the
pattern was the same at the first and second
injection. No more was given, because of this
side effect. Her blood values, however, in-
creased favourably. During a long observation
period this patient has displayed untoward effects
to almost every medicine given, perhaps because
of a defect in the liver function as a result of
an active chronic hepatitis. She has a rather
impressive tendency to iron deficiency.
C om m en ts :
Included in this report is an earlier study,
where the same haematological variables were
R eferences:
American Rheumatism Association: Diagnostic
criteria for population studies. Bull. Rheum.
Dis. 12, 291 , 1962.
Andersson, N.: Investigation of the tolerance
of Astra 2152 (personal communication). 1974.
Andersson, N. , Grafford, K.: Clinical
studies on an iron-poly (sorbitol gluconic acid)
complex for parenteral use (personal communica-
tion). 1975.
Brown, E. B. , Moore, G.V.: Parenter-
ally administered iron in the treatment of hypo-
chromic anaemia. Publ. in "Progress in haemato-
logy (ed. by L. M. TOCANTINS). Vol. I. Grune
& Stratton New York and London 1956.
Cartwright, G. E. , Wintrobe, M.M.:
Chemical, clinical and immunological studies on
the products of human plasma fractionation
XXXIX. The anaemia of infection. Studies on
the iron-binding capacity of serum. J. clin.
Invest. 28, 86, 1949.
Doumas, B. T. : Albumin standards and the
studied in the same way in 20 patients with
rheumatoid arthritis given iron dextrin (Astrafer,
Ferrigen) intravenously and 33 patients with the
same disease receiving iron sorbitol (JectoferW)
intramuscularly.
Compared with Jectofer, Ferastral seems to
have a certain advantage in one respect. In
patients with extremely low UIBC and transferrin
concentrations in serum (and a slight decrease
of MCHC, indicating an iron deficiency component),
as is just the case in patients with active rheuma-
toid arthritis after a few injections with Jectofer
in standard dosage (100 mg Fe daily) there is
often a competition for the unbound iron binding
capacity leading to saturation of the transferrin,
with iron taxicity signs, tachycardia, chills,
sweating, nausea, This sort of reactions was
not obtained in the present series, even in patients
with extremely low concentrations of UIBC and
transferrin.
measurement of serum albumin with bromcresol-
green. Clin. Chim. Acta 31, 87, 1971.
Heilmeyer, L. , Plötner, K.: Das
Serumeisen und die Eisenmangelkrankheit.
Fischer-Verlag, Jena 1937.
Johansson, B. G.: Agarose gel
electrophoresis. Scand. J. clin. Lab. Invest. 29,
Suppl. 124, 21, 1972.
Laurell, C. B.: Electroimmunoassay.
Scand. J. clin. Lab. Invest. 29, Suppl. 124, 21,
1972.
Mc Curdy, P. R.: Parenteral iron therapy.
Publ. in "Iron deficiency", (ed. by L. Hallberg,
H.-G. Harwerth, Vannotti, A). Academic Press,
London and New York 1970 (p. 543).
Strandberg, P.O.: The influence of
corticosteroid therapy on haematological values,
bone marrow iron and iron absorption in patients
with rheumatoid arthritis. Acta Med. Scand. 180,
Suppl. 454, 127, 1966.
Tarukoski, P.: Quantitative spectrophoto-
metric determination of haptoglobin. Scand. J.
clin. Lab. Invest. 18, 80, 1966.
75